Contraceptive vaginal ring reduces lamotrigine levels.

Area of Science:

• Pharmacology
• Epilepsy Management
• Women's Health

Background:

• Oral contraceptives containing estrogen increase lamotrigine clearance, causing variable serum levels.
• The impact of non-oral hormonal contraceptives like the vaginal ring and transdermal patch on lamotrigine pharmacokinetics is not well understood.

Purpose of the Study:

• To investigate the effect of the vaginal ring and transdermal patch on lamotrigine serum concentrations in women with epilepsy.

Main Methods:

• Retrospective chart review of women with epilepsy using vaginal rings or transdermal patches.
• Comparison of dose-corrected lamotrigine plasma concentrations during contraceptive use versus off-contraception periods.
• Statistical analysis using Wilcoxon signed-rank tests for paired data.

Main Results:

• Lamotrigine concentrations decreased significantly (p=0.04) during the active phase of the vaginal ring in most users (5 out of 6 patients).
• Decreases in dose-corrected lamotrigine concentrations ranged from 36% to 70% while on the vaginal ring.
• One patient using a transdermal patch also experienced a 37% decrease in lamotrigine concentration.

Conclusions:

• The vaginal ring contraceptive method reduces lamotrigine concentrations during active use.
• These findings highlight the importance of considering contraceptive choices when managing lamotrigine therapy in women with epilepsy.
• Ensuring therapeutic lamotrigine levels is critical for women of childbearing age with epilepsy using these contraceptive methods.